Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
American Health & Drug Benefits
|
July 24, 2020
A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making
Madison M Wempe, Mark D Stewart, Daniel Glass, et al.
JCO Precision Oncology
|
October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment
Aleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, et al.
Oncology and Therapy
|
June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making
Thomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Journal for Immunotherapy of Cancer
|
September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical and Translational Science
|
March 12, 2025
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Andrew G Hadd, Angela Silvestro, Brittany Avin McKelvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
The Oncologist
|
March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and Assays
Mark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
JCO Precision Oncology
|
August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Diana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
American Health & Drug Benefits
|
July 24, 2020
A National Assessment of Diagnostic Test Use for Patients with Advanced NSCLC and Factors Influencing Physician Decision-Making
Madison M Wempe, Mark D Stewart, Daniel Glass, et al.
JCO Precision Oncology
|
October 30, 2025
Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment
Aleksandra Markovets, Diana Merino Vega, Chris Abbosh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group
Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, et al.
Oncology and Therapy
|
June 13, 2022
Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making
Thomas W LeBlanc, Nigel H Russell, Loriana Hernandez-Aldama, et al.
Journal for Immunotherapy of Cancer
|
September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Clinical and Translational Science
|
March 12, 2025
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Andrew G Hadd, Angela Silvestro, Brittany Avin McKelvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
The Oncologist
|
March 11, 2022
Homologous Recombination Deficiency: Concepts, Definitions, and Assays
Mark D Stewart, Diana Merino Vega, Rebecca C Arend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2025
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Hillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
JCO Precision Oncology
|
August 11, 2022
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Diana Merino Vega, Katherine K Nishimura, Névine Zariffa, et al.
Page
of 1